Business
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
More countries are banning e-cigarettes as novel oral products gain tractionKELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp.
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"More countries are banning e-cigarettes as novel oral products gain tractionKELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces it has been granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office (\"USPTO\").US patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. Lexaria's superior DehydraTECH processing and sublingual compositions have now been recognized not only through exceptional scientific study results, but also by the USPTO.DehydraTECH-nicotine has already shown in multiple sets of animal testing that it can be delivered to the bloodstream up to 10-times to 20-times faster at up to 10-fold higher levels of nicotine into blood plasma from oral absorption than concentration matched controls. Speed of onset is of vital importance to nicotine users.This US-awarded patent is also progressing as a patent application through other jurisdictions internationally. This US patent award and the international patent applications are supported in part by the superior pharmacokinetic blood plasma data generated by Lexaria in its animal studies conducted from 2017 through 2021. Lexaria considers the work completed by competitors to be substantially inferior when it is limited to indirect theoretical extrapolations of nicotine absorption into the bloodstream and/or subjective commentary from small numbers of people, as opposed to Lexaria's rigorous scientific examinations.Lexaria's new patent builds nicely upon its growing patent portfolio in the oral nicotine delivery sector including the white pouch category for both sublingual and buccal tissue delivery, together with its previous patent filings specific to nicotine dating back to 2019, as well as its foundational DehydraTECH patent filings dating back to 2016.The oral nicotine pouch category is of intense interest to Lexaria and the nicotine products industry, and its growth is due in part to its reduced risk health outcomes as noted by the Food and Drug Ad...